Guidelines have been developed to simplify the antimicrobial treatment decision for patients with acute exacerbations of chronic obstructive lung disease. Approximately half of these patients will have a demonstrable bacterial infection and antibiotics have been demonstrated to shorten the clinical illness and prevent significant deterioration. Patients can be stratified by the risk of treatment failure with usual first-line antimicrobial agents. Patients presenting with worsening dyspnea, increased sputum volume and purulence should be offered antimicrobial therapy. In the presence of significant impairment of lung function (FEVI 50% predicted), frequent exacerbations, significant comorbidity, malnutrition, chronic corticosteroid administration and long duration of disease, should be treated with more aggressive therapy such as with a fluoroquinolone, amoxicillin-clavulanate, or a second or third generation cephalosporin or second generation macrolide. In the absence of these risk factors, first-line agents such as amoxicillin appear adequate. Patients with chronic suppurative airway disease (mainly bronchiectasis) should be treated with an antipseudomonal fluoroquinolone if P. aeruginosa is identified in pulmonary secretions. More prospective randomized trial are warranted to validate this approach.
1
American Thoracic Society.
Standard for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma.
Am Rev Respir Dis .
1987;
136
225-244
2
Gonzales R, Steiner J F, Sande M A.
Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians.
JAMA .
1997;
278
901-904
5 Intercontinental Medical Statistics (IMS). Ruislip, Middlesex: BPI/MDI, Sept 1993
6
Huchon G J, Gialdroni-Grassi G, Leophonte P, Manresa F, Schaberg T, Woodhead M.
Initial antibiotic therapy for lower respiratory tract infection in the community: A European survey.
Eur Respir J .
1996;
9
1590-1595
8 Morbidity and Mortality: 1996 Chartbook on Cardiovascular, Lung and Blood Disease. Bethesda, MD: National Heart, Lung and Blood Institute, National Institutes of Health; May 1996: 50
9
Higgens M W, Keller J B, Metzner H L.
Smoking, socioeconomic status and chronic respiratory disease.
Am Rev Respir Dis .
1977;
116
403-410
10
Niederman M S, McCombs J S, Unger A N, Kumar A, Popovian R.
Treatment cost of acute exacerbations of chronic bronchitis.
Clin Ther .
1999;
21
576-592
11
Gump D W, Phillips C A, Forsyth B R, McIntosh K, Lamborn K R, Stouch W H.
Role of infection in chronic bronchitis.
Am Rev Respir Dis .
1976;
113
465-473
13
Monsó E, Ruiz J, Rosell A.
Bacteria infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush.
Am J Respir Crit Care Med .
1995;
152
1316-1320
14
Groeneveld K, van Alphen L, Eijk P P, Visschers G, Hansen H M, Zanen H C.
Endogenous and exogenous reinfections by Haemophilus influenzae in patients with chronic obstructive pulmonary disease: The effect of antibiotic treatment on persistence.
J Infect Dis .
1990;
161
512-517
15
Eller J, Ede A, Schaberg T, Niederman M S, Mauch H, Lode H.
Acute infective exacerbation of chronic bronchitis. Relation between bacterial etiology and lung function.
Chest .
1998;
113
1542-1548
16
Anthonisen N R, Manfreda J, Warren C PW, Herschfield E S, Harding G K, Nelson N A.
Antibiotic therapy in exacerbations of chronic obstructive lung disease.
Ann Intern Med .
1987;
106
196-204
19
MacFarlane J T, Colville A, Guion A, MacFarlane R M, Rose D H.
Prospective study of aetiology and outcome of adult lower-respiratory tract infections in the community.
Lancet .
1993;
341
511-514
20
Doern G V, Brueggemann A, Pierce G, Holley Jr P H, Rauch A.
Antibiotic resistance among clinical isolates of Hemophilus influenzae in the United States in 1994 and 1995 and detection of β-lactamase-positive strains resistant to amoxicillin-clavulanate: Results of a national multicenter surveillance study.
Antimicrob Agents Chemother .
1997;
41
292-297
21
Doern G V, Brueggemann A, Pierce G, Hogan T, Holley Jr P H, Rauch A.
Prevalence of antimicrobial resistance among 723 outpatients clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995; Results of a 30-center national surveillance study.
Antimicrob Agents Chemother .
1996;
40
2884-2886
22
Sportel J H, Koëter G H, van Altena R, Löwenberg A, Boersma W G.
Relation between β-lactamase producing bacteria and patient characteristics in chronic obstructive pulmonary disease.
Thorax .
1995;
50
249-253
23
Adams S, Melo J, Anzueto A.
Effects of antibiotics on the recurrence rates of chronic obstructive pulmonary disease exacerbations.
Chest .
1997;
112
22S
24
Doern G V, Brueggemann A, Holley Jr P H, Rauch A M.
Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995; Results of a 30-center national surveillance study.
Antimicrob Agents Chemother .
1997;
40
1208-1213
25
Thornsberry C, Ogilvie P, Kahn J, Mauriz Y.
Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season.
Diagn Microbiol Infect Dis .
1997;
29
249-257
28
Bakaletz L O, Tallan B M, Hoepf T, DeMaria T F, Birck H G, Lim D J.
Frequency of fimbriation of nontypeable Hemophilus influenzae and its ability to adhere to chinchilla and human respiratory epithelium.
Infect Immun .
1988;
56
331-335
29
Wilson R, Pitt T, Taylor G.
Pyocyanin and 1-hydroxyphenazine produced by Pseudomonas aeroginosa inhibit the beating of human respiratory cilia in vitro.
J Clin Invest .
1987;
79
221-229
30
Adler K B, Hendley D D, Davis G S.
Bacteria associated with obstructive pulmonary disease elaborate extracellular products that stimulate mucin secretion by explants of guinea pig airways.
Am J Pathol .
1986;
125
501-514
31
Farley M M, Stephens D S, Mulks M H.
Pathogenesis of IgA1 protease-producing and non-producing Hemophilus influenzae in human nasopharyngeal organ cultures.
J Infect Dis .
1986;
1547
752-759
32
Paton J C, Ferrante A.
Inhibition of human polymorphonuclear leukocyte respiratory burst, bactericidal activity, and migration by pneumolysin.
Infect Immun .
1983;
41
1212-1216
35
Cundell D R, Taylor G W, Kanthakumar K.
Inhibition of human neutrophil migration in vitro by low-molecular-mass products of nontypeable Haemophilus influenzae Infect Immun .
1993;
61
2419-2424
36
Currie D C, Peters A M, Geroge P.
Indium-111-labelled granulocyte accumulation in respiratory tract of patients with bronchiectasis.
Lancet .
1987;
1
1335-1339
37
Amitani R, Wilson R, Rutman A.
Effects of human neutrophil elastase and Pseudomonas aeroginosa proteases on human respiratory epithelium.
Am J Respir Cell Mol Biol .
1991;
4
26-32
39
Stockley R A, Burnett D.
Serum derived protease inhibitors and leucocyte elastase in sputum and the effect of infections.
Bull Eur Physiolpathol Respir .
1980;
16
261-271
44
Cabello H, Torres A, Celis R.
Bacterial colonization of distal airways in healthy subjects and chronic lung disease: A bronchoscopic study.
Eur Respir J .
1997;
10
1137-1144
46
Pela R, Marchesani F, Agostinelli C.
Airway microbial flora in COPD patients in stable clinical conditions and during exacerbations: A bronchoscopic investigation.
Monaldi Arch Chest Dis .
1998;
53
262-267
47
Dewan N A, Rafique S, Kanwar B.
Acute exacerbations of chronic obstructive lung disease. Factors associated with poor treatment outcomes.
Chest .
2000;
11
662-671
48
Grossman R F, Mukerjee J, Vaughan D.
A one-year community based health economic study of ciprofloxacin versus usual antibiotic treatment in acute exacerbations of chronic bronchitis.
Chest .
1998;
113
131-141
49
Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E.
Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease.
Am J Crit Care Med .
1999;
159
158-164
50
Vestbo J, Prescott E, Lange P, the Copenhagen City Heart Study Group.
Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity.
Am J Respir Crit Care Med .
1996;
153
1530-1535
52
Seneff M G, Wagner D P, Wagner R P, Zimmerman J E, Knaus W A.
Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive lung disease.
JAMA .
1995;
274
1852-1857
59
Dollman A, López Mazzei H, Cukier A.
Consenso Latinamericano sobre infecciones en bronquitis crónica.
Revista Panamericana de Infectología .
1997;
1
3-19
